Beijing Chemclin Biotech Completes Private Placement Of $16.5 Million
This article was originally published in PharmAsia News
Beijing Chemclin Biotech, China's leading in vitro diagnostic reagents and instruments maker, has completed its second round of private placement totalling $16.5 million. The funding is led by China Healthcare Partnership, with participation of first round investors WI Harper Group, Siemens Venture Capital and SB China Venture Capital. Against a background of economic recession, Chemclin's fundraising success shows that investors have confidence in China as well as in the company's development, technology and internationalized management system. Chemclin will next focus on market channel broadening, products development and talent build-up. (Click here for more - Chinese Language)
You may also be interested in...
The US FDA issued only one device-related close-out letter in October.
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.